ArticleBMC urology2025
Predictive value of inflammatory marker PLR in prostate cancer.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer.BMC urology · 2026Article
- Comparative evaluation of composite inflammatory indices for predicting prostate cancer risk and mortality: a NHANES-based study with external validation.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aims to investigate the correlation between inflammatory markers and prostate cancer with a good-quality predictive model.
methodsThe original dataset was randomly split into a training set (70%) and a validation set (30%). Logistic regression was used to examine the related risk factors within the training set. ROC curve analysis was conducted to evaluate the discriminative ability of risk factors for PCa. The accuracy and performance of the prediction model were evaluated using the clinical decision curve and 10-fold cross-validation. The diagnostic value of the model was compared across various PSA regions in the entire dataset. The nomogram was employed to illustrate the predictive model. Additionally, we analyzed the corresponding variables and the relationship between the International Society of Urological Pathology (ISUP) grading of PCa.
resultsAge, prostate volume (PV), total PSA (tPSA), (f/t) PSA, and platelet-to-lymphocyte ratio were identified as independent risk factors for prostate cancer. The predictive model utilizing these parameters has shown significant clinical advantage, stability, and elevated diagnostic efficacy within the PSA range of 4-20 ng/mL. Additionally, significant differences in tPSA and PV were observed among PCa patients with varying ISUP grades.
conclusionPLR can serve as a predictive indicator for prostate cancer and, when integrated with additional clinical data, can enhance the detection rate of prostate cancer. Moreover, there was no correlation between PLR and the ISUP grade of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.